Genenta Science S.p.A. (GNTA) annual cash flow statement — 7-year operating, investing & financing history
| Cash from Operations | -6.87M | -6.24M | -11.21M | -7.42M | -6.96M | -6.04M | -2.49M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | -10.06% | 44.31% | -51.05% | -6.61% | -15.11% | -142.74% | - |
| Net Income | -6.53M | -8.91M | -11.65M | -8.48M | -5.53M | -5.59M | -4.6M |
| Depreciation & Amortization | 28.08K | 44.52K | 42.45K | 6.14K | 4.89K | 1.9K | 0 |
| Stock-Based Compensation | 1.01M | 847.25K | 739.88K | 722.74K | 497.1K | 460.19K | 749.51K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 203.02K | 63.11K | 75.69K | 90.36K | 13.23K | 6.06K | 4.87K |
| Working Capital Changes | -1.58M | 1.72M | -417.6K | 240.3K | -1.94M | -920.72K | 1.35M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.31M | 32.08K | -728.18K | 1M | -365.15K | -17.43K | -27.58K |
| Cash from Investing | -14.54M | 6.88M | -14.89M | -27.07K | -9.01K | -20.87K | 0 |
| Capital Expenditures | -7.63K | -4.47K | -13.79K | -27.07K | -9.01K | -20.87K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -304.99K | 0 | 0 | 0 | 0 |
| Cash from Financing | 22.29M | 270.88K | 531 | 0 | 28.74M | 1.39M | 14.77M |
| Debt Issued (Net) | 7.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 531 | 0 | 28.74M | 1.5M | 15.09M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 14.79M | 270.88K | 0 | 0 | 543 | -111.12K | -318.51K |
| Net Change in Cash | 945.92K | 890.33K | -26.1M | -7.45M | 21.77M | -4.68M | 12.28M |
| Free Cash Flow | -6.88M | -6.24M | -11.22M | -7.45M | -6.97M | -6.07M | -2.49M |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | -10.1% | 44.34% | -50.68% | -6.86% | -14.87% | -143.57% | - |
| FCF per Share | -0.35 | -0.34 | -0.62 | -0.41 | -0.38 | -0.33 | -0.14 |
| FCF Conversion (FCF/Net Income) | 1.10x | 0.67x | 0.98x | 0.90x | 1.21x | 1.16x | 0.55x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying GNTA stock.
Genenta Science S.p.A. (GNTA) generated $-6.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Genenta Science S.p.A. (GNTA) reported negative free cash flow of $6.9M in 2025, indicating capital requirements exceeded cash from operations.
Genenta Science S.p.A. (GNTA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.